DNMT3A and myeloproliferative neoplasm: Although it was shown that patients with a DNMT3A mutation were more likely to have a favorable response to hypomethylating therapy used in the treatment of MDS, MDS/MPN and secondary AML (42), the conclusion was not supported by other studies (43, 44).